Nonmelanoma skin cancer (NMSC) includes actinic keratosis (AK) (premalignant lesion), Bowen’s disease (BD), cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), and extramammary Paget’s disease (EMPD). NMSC is more likely to affect older adults, particularly in areas such as the head, face, or genital regions. It often presents as multiple or extensive lesions, which makes treatment challenging and increases the risk of recurrence. ALA-PDT for NMSCs is recognized for its safety and repeatability. It does not damage the structure or function of surrounding normal tissues, can induce antitumor immunity, and may reduce the likelihood of recurrence or metastasis. ALA-PDT was first used internationally to treat AK and BCC in 1990. In China, it began to be applied for the treatment of BD, superficial BCC, and cSCC in 1996. The importance of ALA-PDT in treating NMSC is increasing, with treatment methods continually being refined and expanded. The proposed M-PDT protocol is expected to alleviate treatment pain and provide a comfortable and healthy diagnostic and therapeutic experience. Adjuvant and neoadjuvant photodynamic therapy, when used in conjunction with surgery or laser treatment, can enhance the benefits of these interventions. This approach provides personalized treatment options that may improve the treatment efficacy and patient prognosis for NMSC patients.